外围足球论坛: WHO likely to grant Chinese vaccines emergency use by April

2021-04-02 13:53:15Global Times Editor : Wang Yifan ECNS App Download
Special: Battle Against Novel Coronavirus 本文来源:

申博官方网址,记者用“跟自己打了一架”来形容这个过程,他点了点头。  马库斯在2015年的1月31日武林风比赛中被方便TKO,遭遇啥职业生涯第二次KO/TKO落败。  在过去的10年中,中国的搏击格斗分为了几块,大部分的比赛如《武林风》、《昆仑决》、《英雄传说》、《勇士的荣耀》等赛事,都主攻踢拳、有的还搂草打兔子,兼顾MMA,出赛的选手主要来自社会上的俱乐部。葡方明确表示,愿加强同中方在“一带一路”框架下的合作,希望中国企业在葡合作建设一批重要项目,使葡成为“一带一路”建设的重要节点。


  我们中国的文化,其实我说第二个障碍,就是说我们中国的文化目前来说不具有那么强的包容性,中国不是一个移民国家,当然,过去我们可能人口太多了,有控制,但是总体来讲,世界上,世界各国的优秀的人才,你让他到硅谷去,他是愿意的,他觉得那里不仅是全球创新的中心,而且大家都说同样的语言,说英语,在中国,我们做不到这一点。31岁的拉维奇效力中超河北华夏幸福,根据“FootballLeaks”披露的合同文件,拉维奇在中超的工资,远高于梅西或C罗,阿根廷前锋在华夏幸福的周薪是49万3千英镑!而且还是税后!疯狂的钱啊!如果进行换算,拉维奇的年薪大约是2563万欧元,折合3013万欧左右,这个数额要远远高出C罗和梅西。  经消防官兵现场侦查发现,牛棚东西两侧进出口的砖墙随时可能发生二次坍塌,消防官兵无法从进出口进入棚内救援,只能从羊棚的侧墙挖出口进入,然后用切割机将羊棚龙骨的钢筋切断,再用剪扩器将钢条剪断,解救被困羊群。自从2010年巡唱世界各地、演出46场之后,王菲一直处于休息状态。

Sinovac and Sinopharm COVID-19 vaccines are likely to be included into the emergency use list of the World Health Organization (WHO) by the end of April despite WHO experts saying that data of the vaccines on elderly people are lacking.

Chinese vaccine makers Sinopharm and Sinovac have presented data on their COVID-19 vaccines indicating levels of efficacy that would be compatible with those required by the WHO standard, which means an efficacy of about 50 percent and preferably close to or above 70 percent, WHO's Strategic Advisory Group of Experts (SAGE) chair Alejandro Cravioto said on Wednesday, Reuters reported.

The SAGE hopes to issue recommendations on those Chinese vaccines by the end of April, Cravioto said, noting that the vaccines would first require emergency use listing from the WHO or from what the agency considers to be a stringent regulatory authority before SAGE experts can make recommendations about their use.

Chinese producers Sinopharm and Sinovac have applied to be included into WHO's emergency use list. The WHO sent experts to investigate their production workshops in Beijing in February.

Chinese experts deemed that the lack of data on the elderly group would not be an issue to hinder the process.

The data Sinopharm and Sinovac submitted to the WHO was the data from their Phase III clinical trials. And there were not so many elderly volunteers who participated in the Phase III trials.

But so far, Chinese vaccines have been used in many countries on a large number of elderly people, which proves their efficacy and safety, Zeng Guang, former chief epidemiologist of the Chinese Center for Disease Control and Prevention, told the Global Times on Thursday.

But the WHO suggestions are worthy of consideration for Chinese producers as they should learn to timely submit data in the future, Zeng noted.

Yang Xiaoming, CEO of the China National Biotec Group of Sinopharm, previously told media that out of consideration of safety, the group launched Phase III clinical trials on people aged 18-59 first, then trials on people aged 60 and above and, at last, on the minors.

But as trials and application of the vaccines proceeds, China has expanded domestic vaccination program to people aged 60 and above. Many foreign countries applying Sinopharm and Sinovac vaccines, including Brazil, Chile and Turkey, even prioritized elderly people in their vaccination drives.

Sinovac CEO Yin Weidong suggested prioritizing elderly people with chronic diseases in vaccination drives as the vaccines can effectively protect these people, a high-risk infection group.

Tao Lina, a Shanghai-based vaccine expert, told the Global Times on Thursday during WHO's review on Chinese vaccines that safety should be more important than efficacy as efficacy can be improved through vaccination procedures. For example, a third dose can be administered to recipients who cannot produce enough antibodies after two shots.

The Global Times learned that Sinopharm and Sinovac are doing research on whether a third dose can enhance antibody levels and overall efficacy of the vaccines against the coronavirus, and how effective the vaccines are on mutated sequences.

Tao's comments came after at least 15 European countries halted their roll-out of the Oxford-AstraZeneca vaccine, one of the three COVID-19 vaccines on the WHO emergency use list, following reports that some inoculated people died due to blood clots after taking doses of the vaccine.

The other two COVID-19 vaccines on the WHO emergency use list are separately produced by Pfizer/BioNTech and Johnson & Johnson.

Related news


Most popular in 24h

MoreTop news


Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2021 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
申博游戏注册 菲律宾申博官网登入 申博开户平台登入 菲律宾申博娱乐直营官网 正规申博开户登入 申博会员现金网直营网 菲律宾申博官网直营网 菲律宾申博直营网 申博官网下载登入 申博138娱乐直营网
申博娱乐网址 菲律宾申博游戏登入 网上百家乐登入 百家乐微信支付充值 菲律宾申博太阳网城上娱乐